Skip to content

Author

Nadia Harbeck

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)

The Advanced Breast Cancer (ABC) 8th international consensus conference took place on 6-8 November 2025, in Lisbon, and updated the previous ABC international consensus guidelines that are described in this manuscript. These guidelines reflect the work of a large and global consensus panel, comprising healthcare profes...

F. Cardoso, J. Ribeiro, E. Schumacher-Wulf et al. · 0 citations
Open access 2026

TROFUSE-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hr+/her2– breast cancer

Sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells, demonstrated significant progression-free survival and overall survival benefits compared with chemotherapy in metastatic TNBC.

R. Freitas-Júnior, P. Schmid, Jing Wei et al. · 0 citations
Review Open access Sep 2026

Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis.

BACKGROUND AND PURPOSE The treatment landscape for breast cancer has undergone significant advancements in the recent years, with the introduction of several new anticancer agents, especially those belonging to the antibody-drug conjugates (ADCs) class. However, there exists a lack of comprehensive evidence regarding t...

L. Visani, C. Becherini, M. Kubeczko et al. · 0 citations
Open access Aug 2026

Metastatic founder cell candidates resemble preimplantation embryonic blastomeres

Disseminated cancer cells (DCC) in non-metastatic carcinoma patient bone marrow (BM) are predictive of metastasis. Those detected by epithelial cytokeratin or EpCAM expression have poorly-characterized transcription profiles due to their extreme rarity: 1∼2 cells per 2x 106 BM cells in every third non-metastatic patien...

Huiqin Körkel-Qu, Elia Raya, M. Gužvić et al. · 0 citations
Clinical trial Sep 2026

Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.

PURPOSE Circulating tumor DNA (ctDNA) may serve as a biomarker to facilitate early identification of asymptomatic distant tumor spread in patients with breast cancer. The primary objective of this study was to assess clinical validity and prognostic value of post-treatment tissue-free ctDNA detection by evaluating its...

T. Friedl, P. Fasching, A. Hartkopf et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.